We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Share News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.50
Bid: 11.50
Ask: 13.50
Change: -0.25 (-1.96%)
Spread: 2.00 (17.391%)
Open: 12.75
High: 12.75
Low: 12.50
Prev. Close: 12.75
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Redx Surges On Potential Takeover Offer

Tue, 31st Dec 2019 10:34

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.

----------

FTSE 100 - LOSERS

----------

HSBC, down 0.6%. The bank is planning to expand its exchange traded fund range in 2020 in order to revitalise its underperforming asset management business, the Financial Times reported. Nicholas Moreau, who was appointed chief executive of HSBC's asset management division in August, has devised a series of initiatives aimed at reinvigorating growth at a time when the London-listed bank is aggressively cutting costs, the FT said. In the first half of 2020, HSBC will launch eight ETF's employing environmental, social and governance metrics to tap into rising investor demand for ESG-focused strategies. HSBC also plans to develop a fixed income ETF platform in 2020 and to launch a range of precious metals tracker funds later in the year, the FT noted.

----------

FTSE 250 - WINNERS

----------

CLS Holdings, up 0.8%. The company said it will sell a portfolio of 19 regional offices in the UK for GBP65.0 million to Capital Partners, a Singaporean investment firm. The offices are located across the UK outside of the South East. Therefore the sale is in line with the FTSE 250-listed company's strategy of actively recycling its capital and focusing the UK portfolio on London and the South East, it said. Following the completion of the transaction, CLS will hold only two assets in the UK outside of the South East. "We continue to see significant opportunities for acquisitions across our core markets, and this transaction will allow us to recycle capital to capitalise on those opportunities," explained Chief Executive Fredrik Widlund.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Redx Pharma, up 28%. The drug discovery and development company said it has been in discussions with Samuel Waksal, the founder of ImClone Systems and Kadmon Pharmaceuticals, about a possible cash takeover offer. Redx cautioned, however, there was as yet no "firm intention" to make an offer and there can be no certainty that the offer will be made. Waksal has until 1700 GMT on January 28 to make a firm offer, the company said. Redx also said it has been in discussions with shareholders and third-party healthcare specialist investors regarding longer-term funding of the company, in order to advance its medicines for cancer and fibrosis to the next stage trials. Therefore the company is asking shareholders for permission to agree to the capitalisation of a GBP2.5 million loan into ordinary shares at 5.25 pence per share. Back in June, the company had signed a loan agreement with Moulton Goodies - which has 18% stake in Redx - for a fixed-rate secured loan note facility of up to GBP2.5 million.

----------

Lansdowne Oil & Gas, up 18%. The exploration company said it has further extended the repayment date of its outstanding GBP1.0 million loan with LC Capital Master Fund, which had been due on Tuesday, to June 30 next year. The move follows a previous half-year extension, reported on June 28. Also at that time, the AIM-listed company had secured debt funding of GBP150,000 from LC Capital and GBP150,000 from Brandon Hill Capital by way of loan note. Lansdowne said that debt facility was expected to provide sufficient funds to carry the company through to the end of 2019. The company did not provide any further update regarding its cash position.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Bango, down 9.2%. The mobile commerce company reported continued growth in end-user spend, which is expected to achieve GBP1.1 billion in 2019, resulting in revenue growth for the year of 40% to "at least" GBP9.3 million. Adjusted earnings before interest, taxes, depreciation, and amortization for the full year is positive and in excess of GBP400,000. The year before, the company recorded an adjusted Ebitda loss of GBP870,000. However, this strong results will be still below market forecasts primarily due to a Customer Data Platform license and Marketplace supply deal not concluding in December as expected. These deals are now expected to close in early 2020, Bango said. The company said operating costs remain stable and in line with expectations. Bango said it continues to invest in research & development, growing the data monetisation business and boosting the Bango platform.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
12 Apr 2024 15:35

Director dealings: Redx Pharma CEO ups stake

(Sharecast News) - Redx Pharma revealed on Friday that chief executive Lisa Anson had acquired 399,000 ordinary shares in the AIM-listed clinical-stage biopharmaceutical firm.

Read more
2 Apr 2024 16:57

LONDON MARKET CLOSE: Europe down after Easter holiday weekend

(Alliance News) - The FTSE 100 took a hit on Tuesday, after a boost from London's miners and oil firms were not enough to lift the index.

Read more
2 Apr 2024 12:15

Redx Pharma plummets on plans to delist from AIM

(Alliance News) - Redx Pharma PLC shares fell on Tuesday, after it said it intends to cancel its shares from trading on AIM in London.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:50

AIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delist

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
14 Feb 2024 09:34

IN BRIEF: Redx Pharma clarifies not currently pursuing US listing

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Responds to a Times article published on Tuesday saying RedX is looking to list its shares in New York. Redx says it "wishes to clarify that it is not currently in any process relating to a listing in the US, nor any other jurisdiction".

Read more
7 Feb 2024 11:08

Redx Pharma shares skyrocket on deal to sell inhibitor program

(Alliance News) - Redx Pharma PLC on Wednesday said it has struck a deal to sell Kirsten rat sarcoma virus inhibitor program to Dublin-based Jazz Pharmaceuticals PLC.

Read more
7 Feb 2024 09:29

AIM WINNERS & LOSERS: Verditek falls on cash shell plans

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
15 Dec 2023 21:09

EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
18 Oct 2023 12:30

Redx Pharma looks to progress portfolio after raising GBP14.1 million

(Alliance News) - Redx Pharma PLC on Wednesday said that it has conditionally raised around GBP14.1 million by way of a subscription for 54.1 million shares at 26 pence each.

Read more
21 Aug 2023 10:29

AIM WINNERS & LOSERS: Fulcrum Utility to leave AIM as loss widens

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
21 Aug 2023 09:33

Redx Pharma says RXC007 receives orphan drug designation from US FDA

(Alliance News) - Redx Pharma PLC on Monday said its RXC007 drug has received orphan drug designation from the US Food & Drug Administration for the treatment of idiopathic pulmonary fibrosis, a condition causing breathing difficulty due to lung scarring.

Read more
21 Aug 2023 07:43

LONDON BRIEFING: Crest Nicholson lowers annual profit forecast

(Alliance News) - Stocks in London are called flat on Monday, with little in the way of economic data or company updates to reignite risk appetite.

Read more
10 Jul 2023 11:22

Redx Pharma extends term of outstanding notes with two lenders to 2024

(Alliance News) - Redx Pharma PLC on Monday said it extended the term of its outstanding convertible loan notes issued to two lenders RM Special Holdings 3 LLC, otherwise known as Redmile, and Sofinnova Crossover I SLP by a year.

Read more
17 May 2023 14:44

Redx Pharma half-year loss doubles amid costs of failed Jounce merger

(Alliance News) - Redx Pharma PLC on Wednesday said its half-year loss nearly doubled, due to lower revenue and higher expenses, but it noted progress in therapeutics trials and said it "retains the foundations for longer term success".

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.